Drug Profile

Peretinoin - Kowa

Alternative Names: K-333; NIK-333

Latest Information Update: 28 Dec 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Kowa Pharmaceutical
Class Antineoplastics; Diterpenes; Retinoids; Skin disorder therapies; Small molecules
Mechanism of Action Apoptosis stimulants; Retinoid X receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Liver cancer
New Molecular Entity No

Highest Development Phases

Phase III Liver cancer

Most Recent Events

28 Dec 2022 Discontinued - Phase-I for Liver cancer (Recurrent) in European Union (PO)
28 Apr 2020 No recent reports of development identified for phase-I development in Liver-cancer(Recurrent) in European Union (PO, Tablet)
17 Apr 2018 Phase I development for liver cancer (Recurrent) is ongoing in European Union (Kowa pipeline, April 2018)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com